Investigating the mechanism of Jiawei Xiaoyao San in treating metabolic associated fatty liver disease (MAFLD) based on the ileal microbiota-bile acid-FXR axis

IF 1.7 Q2 Medicine

Advances in integrative medicine Pub Date : 2025-08-21 DOI:10.1016/j.aimed.2025.100567

Taotao Wei , Gaozhong Dai , Tianye Liu , Yaozhou Tian

{"title":"Investigating the mechanism of Jiawei Xiaoyao San in treating metabolic associated fatty liver disease (MAFLD) based on the ileal microbiota-bile acid-FXR axis","authors":"Taotao Wei , Gaozhong Dai , Tianye Liu , Yaozhou Tian","doi":"10.1016/j.aimed.2025.100567","DOIUrl":null,"url":null,"abstract":"<div><div>Metabolic Associated Fatty Liver Disease (MAFLD) has become a main cause of chronic liver disease globally, necessitating the development of preventive and early therapeutic strategies. Traditional Chinese Medicine (TCM) plays a significant role in human metabolism, and Jiawei Xiaoyao San (JWXYS) has demonstrated notable ameliorative effects on liver stagnation and spleen deficiency-type liver disease. However, its potential mechanisms are still unclear. This study aimed to explore the therapeutic mechanism of JWXYS in treating chronic liver disease by establishing a rat model induced by a high-fat diet. The results revealed that JWXYS could reduce serum levels of total cholesterol (TC) triglycerides (TG) and aspartate aminotransferase (AST) in model rats, significantly improve the structure of liver lobule, reduce lipid deposition in hepatocytes, and reduce the abundance of harmful intestinal flora (such as <em>Staphylococcus</em> and <em>Enterococcus</em>). In addition, JWXYS improved gut microbiota imbalance, regulated bile acid and lipid metabolism, and maintained the overall health of rats. These findings provide a theoretical basis for using JWXYS to treat chronic fatty liver disease.</div></div>","PeriodicalId":7343,"journal":{"name":"Advances in integrative medicine","volume":"12 4","pages":"Article 100567"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in integrative medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212958825001260","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Metabolic Associated Fatty Liver Disease (MAFLD) has become a main cause of chronic liver disease globally, necessitating the development of preventive and early therapeutic strategies. Traditional Chinese Medicine (TCM) plays a significant role in human metabolism, and Jiawei Xiaoyao San (JWXYS) has demonstrated notable ameliorative effects on liver stagnation and spleen deficiency-type liver disease. However, its potential mechanisms are still unclear. This study aimed to explore the therapeutic mechanism of JWXYS in treating chronic liver disease by establishing a rat model induced by a high-fat diet. The results revealed that JWXYS could reduce serum levels of total cholesterol (TC) triglycerides (TG) and aspartate aminotransferase (AST) in model rats, significantly improve the structure of liver lobule, reduce lipid deposition in hepatocytes, and reduce the abundance of harmful intestinal flora (such as Staphylococcus and Enterococcus). In addition, JWXYS improved gut microbiota imbalance, regulated bile acid and lipid metabolism, and maintained the overall health of rats. These findings provide a theoretical basis for using JWXYS to treat chronic fatty liver disease.

查看原文本刊更多论文

基于回肠微生物群-胆汁酸- fxr轴研究加味消药散治疗代谢性脂肪肝的机制

代谢性相关脂肪性肝病（MAFLD）已成为全球慢性肝病的主要病因，需要制定预防和早期治疗策略。中药在人体代谢中发挥着重要作用，加味逍遥散对肝郁脾虚型肝病有显著的改善作用。然而，其潜在机制尚不清楚。本研究旨在通过建立高脂饮食诱导的大鼠模型，探讨JWXYS治疗慢性肝病的作用机制。结果显示，JWXYS可降低模型大鼠血清总胆固醇（TC）、甘油三酯（TG）和天冬氨酸转氨酶（AST）水平，显著改善肝小叶结构，减少肝细胞脂质沉积，降低肠道有害菌群（如葡萄球菌和肠球菌）丰度。此外，JWXYS还能改善肠道菌群失衡，调节胆汁酸和脂质代谢，维持大鼠整体健康。本研究结果为JWXYS治疗慢性脂肪肝提供了理论依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in integrative medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-

CiteScore

3.20

自引率

11.80%

发文量

审稿时长

15 weeks

期刊介绍： Advances in Integrative Medicine (AIMED) is an international peer-reviewed, evidence-based research and review journal that is multi-disciplinary within the fields of Integrative and Complementary Medicine. The journal focuses on rigorous quantitative and qualitative research including systematic reviews, clinical trials and surveys, whilst also welcoming medical hypotheses and clinically-relevant articles and case studies disclosing practical learning tools for the consulting practitioner. By promoting research and practice excellence in the field, and cross collaboration between relevant practitioner groups and associations, the journal aims to advance the practice of IM, identify areas for future research, and improve patient health outcomes. International networking is encouraged through clinical innovation, the establishment of best practice and by providing opportunities for cooperation between organisations and communities.